Electrical system for the treatment of the target

Abstract

This provides systems and methods for treating various types of cancer. [Problem to be Solved] The system and method of this disclosure are directed toward the treatment of medical conditions, particularly various types of cancer, by applying low-energy radiotherapy. This apparatus and method provides treatment of a patient's medical condition, particularly type of cancer, by applying low-energy radiofrequency radiation specific to a particular disease to the patient. This apparatus uses a high-precision frequency synthesizer to generate radiofrequency radiation that is amplitude-modulated at identified tumor-specific frequencies for application to the patient during treatment.

Description

Technical Field

[0001] Related Applications This application claims priority under 35 USC§119(C) to U.S. Provisional Patent Application Serial No. 62 / 923,908, filed October 21, 2019, and U.S. Provisional Patent Application Serial No. 62 / 934,212, filed November 12, 2019, which are hereby incorporated by reference in their entirety.

[0002] Technical Field The present invention relates to systems and methods for treating a subject using low - energy high - frequency radiation. The electronic system and its programmed control include directly or indirectly affecting the growth or proliferation of cancerous cells in a warm - blooded mammalian subject and have therapeutic uses for affecting cell function (or dysfunction). The devices and methods of the present invention provide treatment for various cancer types by applying an electromagnetic field amplitude - modulated at a cancer - specific frequency to a patient.

Background Art

[0003] Regarding the effects of very low - energy electromagnetic fields on a subject, reference is made to European Patent No. 0592851 (B1) and corresponding patents and patent applications, as well as various publications referred to therein. There are many additional publications regarding the effects of very low - energy electromagnetic fields on patients suffering from insomnia and / or anxiety disorders, as follows. · Koziol, J. A., Erman, M., Pasche B., Hajdukovic R., Mitler, M. M., (1993), “Assessing a changepoint in a sequence of repeated measurements with application to a low - energy emission therapy sleep study”. J. Applied Statistics 20: 393 - 400; ·        Amato, D., Pasche, B., (1993), “An evaluation of the safety of low energy emission therapy”. Compr Ther 19:242–247; · Higgs , L. , Reite , M. , Barbault , A. , Lebet , JP , Rossel , C. , Amato , D. , Dafni , U. , Pasche . B., (1994), “Subjective and Objective Relaxation Effects of Low Energy Emission Therapy”. Stress Medicine 10:5-13; · Reite , M. , Higgs , L , Lebet , JP , Barbault , A. , Rossel , C. , Kuster , N. , Dafni , U. , Amato , D. , Pasche , B. , (1994). Bioelectromagnetics 15: 67-75. ·        Lebet, JP, Barbault, A., Rossel, C., Tomic, Z., Reite, M., Higgs, L., Dafni, U., Amato, D., Pasche, B., (1996). Ann Biomed Light 24:424–429; · Pasche, B., Erman, M., Hayduk, R., Mitler, M., Reite, M., Higgs, L., Dafni, U., Amato, D., Rossel, C., Kuster, N., Barbault, A., Lebet, JP, (1996), “Effects of Low Energy Emission Therapy in chronic psychophysiological insomnia”. Sleep 19: 327-336; · Kelly, TL, Kripke, DF, Hayduk, R., Ryman, D., Pasche, B., Barbault, A., (1997), “Bright light and LEET effects on circadian rhythms, sleep and cognitive performance”. Stress Medicine 13: 251-258; and · Pasche, B., Barbault, A., (2003), “Low-Energy Emission Therapy Current Status and Future Directions. In Bioelectromagnetic Medicine”, Rosch, PJ, Markov, MS (eds.), pages 321-327, Marcel Dekker, Inc.: New York, NY

[0004] The above publications relate to the prior apparatus, systems, and their use described in the aforementioned European Patent No. 0592851(B1).

[0005] The use of electromagnetic energy generators and electromagnetic energy for treating living mammalian subjects harboring cancerous cells as described in the literature includes U.S. Patent No. 5,908,441, issued to James E. Baer on June 1, 1999, and the references cited herein, as well as the so-called “NovoCure technology,” which involves in vivo implantation of electrodes on either side of tumor growth. The method of this patent is invasive because it involves the implantation of electrodes in the patient. This may also make the method unsuitable for treating certain tumor types. The patent does not anticipate very low energy radiation of electromagnetic energy, including amplitude-modulated high-frequency carrier signals, as required with respect to the present invention.

[0006] U.S. Patent No. 5,690,692, issued on November 25, 1997, entitled “Bioactive Frequency Generator and Method,” describes a programmable control for instructing a frequency synthesizer to enable the generation of an electric current at a specific precise frequency signal or a series of specific precise frequency signals having a square wave within an accuracy of 0.001 Hz. The patent envisions amplifying the voltage of the generated signal and applying the signal to the subject at a specific precise frequency, or continuously at a series of specific precise frequencies by electrodes held by or otherwise connected to the subject (which may be a mammal or food). The patent also does not envision very low energy radiation of electromagnetic energy, including amplitude-modulated high-frequency carrier signals, as required with respect to the invention.

[0007] U.S. Patent No. 8,977,365, issued on March 10, 2015, entitled “Electronic System for Influencing Cellular Function in Warm-Blooded Mammals,” describes an electrically activated electronic system that is useful for influencing cellular function or dysfunction in warm-blooded mammals. The system comprises one or more controllable low-energy HF (high-frequency) carrier signal generator circuits, one or more data processors for receiving control information, one or more amplitude modulation control generators, and one or more amplitude modulation frequency control generators. The amplitude modulation frequency control generators are adapted to precisely control the amplitude modulation frequency with respect to one or more determined or predetermined reference amplitude modulation frequencies with an accuracy of at least 1000 ppm, most preferably about 1 ppm. An improved electronic system and its programmed control, as described in U.S. Patent No. 8,977,365, has been shown to directly or indirectly influence the growth or proliferation of cancer cells in warm-blooded mammalian subjects, and this patent utilizes an analog synthesizer to generate a carrier signal and produce a superior output signal.

[0008] The apparatus and methods of the present invention are generally non-invasive and do not require implanted electrodes. The methods and apparatus provided herein apply very low-energy radiation of electromagnetic energy with a precisely determined amplitude modulation frequency to a patient, particularly for the treatment of cancer.

[0009] Improved cancer treatments are greatly needed to expand cancer treatment options. The need for treatments for difficult-to-treat or treatment-resistant cancers, such as refractory cancers, cancers for which other treatment options have become ineffective, and metastatic cancers, particularly those with metastases to the bone and brain, is especially critical. The systems and methods of this disclosure provide cancer treatments that meet these and other needs, as will be discussed in detail below. [Overview of the project]

[0010] The systems and methods of this disclosure are directed toward the treatment of various types of cancer by applying low-energy radiotherapy. Such systems and methods are intended to affect not only cellular function (or dysfunction) that leads to central nervous system (CNS) damage, but more specifically, directly or indirectly affect the growth or proliferation of cancer cells in warm-blooded mammalian subjects, and are intended to find therapeutic applications for affecting other cellular function (or dysfunction). Direct or indirect effects on cancerous cell growth may include, but are not limited to, any effects on cellular function such as the prophylactic avoidance of cancer cell formation, e.g., inhibition of cancerous cell growth or proliferation, and / or effects on leukocyte function that may lead to the death of cancer cells harboring in warm-blooded mammalian subjects.

[0011] In one embodiment, the present invention provides an apparatus for treating a subject suffering from cancer, the apparatus comprising (i) a conductive applicator configured to apply low-energy radiofrequency radiation to the subject, the low-energy radiofrequency radiation comprising one or more amplitude-modulated output signals, and (ii) a frequency synthesizer coupled to the conductive applicator and configured to generate one or more amplitude-modulated output signals by generating a carrier frequency signal having a carrier frequency from about 1 kHz to 5000 MHz and one or more amplitude-modulated frequency signals having amplitude modulation frequencies from about 0.1 Hz to about 150,000 Hz, wherein the amplitude modulation frequencies are selected to be cancer-specific frequencies.

[0012] A frequency synthesizer may be a digital frequency synthesizer comprising: (i) a digital carrier frequency synthesizer configured to output a carrier frequency signal; (ii) a digital modulated frequency synthesizer configured to output one or more amplitude modulated frequency signals; (iii) an arithmetic logic unit (ALU) configured to numerically calculate one or more digital modulated signals in real time from the carrier frequency signal and the modulated frequency digital signal; and (iv) a digital-to-analog converter (DAC) configured to convert one or more digital modulated signals into one or more amplitude modulated output signals.

[0013] In another embodiment, the present invention provides a method for treating a subject suffering from cancer, the method comprising exposing the subject to low-energy radiofrequency radiation, the low-energy radiofrequency radiation comprising one or more amplitude-modulated output signals, the one or more amplitude-modulated output signals having a carrier frequency from about 1 kHz to 5000 MHz and an amplitude-modulated frequency from about 0.1 Hz to about 150,000 Hz, the amplitude-modulated frequencies being selected to be cancer-specific frequencies, and the subject being treated at one or more of the cancer-specific amplitude-modulated frequencies disclosed herein, or 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more.

[0014] In another embodiment, the apparatus and methods disclosed herein utilize the specific absorption rate (SAR) of low-energy radiofrequency radiation absorbed by a patient, ranging from about 1 microwatt per kilogram of tissue to about 50 watts per kilogram of tissue, from about 100 microwatts per kilogram of tissue to about 10 watts per kilogram of tissue, or from about 0.02 milliwatts per kilogram of tissue to about 400 milliwatts per kilogram of tissue. The low-energy radiofrequency radiation is applied to the target to be treated via a conductive probe, which may be configured to come into contact with the mucous membrane or skin of the target.

[0015] In another embodiment, the frequency synthesizer is a digital frequency synthesizer comprising: a digital carrier frequency synthesizer configured to output a carrier frequency signal; a digital modulated frequency synthesizer configured to output one or more amplitude modulated frequency signals; an arithmetic logic unit (ALU) configured to numerically calculate one or more digital modulated signals in real time from the carrier frequency signal and the modulated frequency digital signal; and a digital-to-analog converter (DAC) configured to convert one or more digital modulated signals into one or more amplitude modulated output signals.

[0016] The methods and apparatuses disclosed herein can be used for the treatment of a variety of cancers, including breast cancer, neuroendocrine tumors, non-Hodgkin lymphoma, adenocarcinoma, head and neck cancer, gastric cancer, glioblastoma, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma, thyroid cancer, prostate cancer, rhabdomyosarcoma, lung cancer, kidney cancer, ovarian cancer, bladder cancer, leiomyosarcoma, myeloma, lymphoma, leukemia, chronic lymphocytic leukemia, brain tumors, and colorectal cancer.

Brief Description of the Drawings

[0017] [Figure 1] Figure 1 shows an exemplary system for applying low-energy electromagnetic radiation to a subject.

[0018] [Figure 2] Figure 2 shows a block diagram of an exemplary radiation device for applying low-energy electromagnetic radiation to a subject.

[0019] [Figure 3] Figure 3 shows a block diagram of an exemplary digital frequency synthesizer of the radiation device of Figure 2.

[0020] [Figure 4] Figure 4 shows a block diagram of a controller of the radiation device of Figure 2.

[0021] [Figure 5] Figure 5 shows an exemplary amplitude-modulated output signal.

[0022] [Figure 6] Figure 6 shows a block diagram of internal hardware included in any of the electronic components of the radiation device of Figure 2.

Mode for Carrying Out the Invention

[0023] As used herein, the singular forms “a,” “an,” and “the” include their plural counterparts unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. As used herein, the term “comprising” (or “comprises”) means “including” (or “includes”). As used herein, the term “exemplary” is intended to mean “as an example” and is not intended to indicate that a particular exemplary item is preferred or required.

[0024] In this document, where such terms “first” and “second” are used to modify nouns or phrases, such use is intended simply to distinguish one item from another and not to require an order unless otherwise specified. When the term “approximately” is used in relation to a number, it is intended to include a number that is close to the number but not exact. For example, in some embodiments, the term “approximately” may include a number within + / - 10 percent of the number.

[0025] This disclosure relates, in general terms, to methods and apparatus for using low-energy radiotherapy, which uses specific frequencies of radio frequency (RF) radiation to apply low-energy radio frequency (RF) electromagnetic fields to warm-blooded mammalian subjects for the treatment of various forms of cancer. The disclosures of European Patent No. 0592851(B1) and U.S. Patent No. 8,977,365 ("365 Patent") are incorporated herein by reference in their entirety.

[0026] The terms related to this document include the following:

[0027] "Electronic device" or "computing device" refers to a device or system comprising a processor and memory. Each device may have its own processor and / or memory, or the processor and / or memory may be shared with other devices, such as a virtual machine or container configuration. When executed by the processor, the memory contains or receives program instructions that cause the electronic device to perform one or more actions according to the program instructions. Examples of electronic devices include personal computers, servers, mainframes, virtual machines, containers, game systems, televisions, digital home assistants, and mobile electronic devices such as smartphones, fitness trackers, and wearable virtual reality devices. Electronic devices may also include internet-connected wearables such as smartwatches, smart clothing, and smart eyewear. Furthermore, electronic devices may be connected to a target by any means that provides appropriate transmission of frequencies to the target, embedded in a product designed for human use during treatment, such as a spoon-shaped probe. However, this is not limited to devices that make direct contact with the mucous membrane of the target, such as a spoon-shaped or other shaped probe, devices that make contact with the skin of the target, such as a band or patch, or means that transmit frequencies without direct contact with the target. In a client-server configuration, the client device and the server are electronic devices, and the server contains instructions and / or data that the client device accesses via one or more communication links in one or more communication networks. In a virtual machine configuration, the server may be an electronic device, and each virtual machine or container may be considered an electronic device. In the following description, client devices, server devices, virtual machines, or containers may be simply referred to as “devices” for brevity. Additional elements that may be included in an electronic device are discussed below in the context of Figure 6.

[0028] The terms “processor” and “processing unit” refer to hardware components of an electronic device configured to execute program instructions. Unless otherwise specified, the singular terms “processor” and “processing unit” are intended to include both embodiments of a single processing unit and embodiments in which multiple processing units perform processing together or collectively.

[0029] The terms “memory,” “memory device,” “data store,” and “data storage facility” refer to non-temporary devices that store computer-readable data, program instructions, or both. Unless otherwise specified, the terms “memory,” “memory device,” “data store,” and “data storage facility” are intended to include embodiments of a single device, and embodiments in which multiple memory devices together or collectively store a set of data or instructions as well as individual sectors within such devices.

[0030] As used herein, the terms “treat,” “treating,” or “stimulating” refer to any process, action, application, treatment, etc. Medical assistance is provided to a subject (or patient), including a human being, with the aim of directly or indirectly improving the subject’s condition, slowing the progression of the subject’s condition or disorder, or improving at least one symptom of a disease or disorder being treated.

[0031] As used herein, the terms “patient” or “subject” refer to any animal, preferably a mammal, more preferably a human, and include, but are not limited to, domestic livestock, primates, and humans, such as humans, non-human primates, cattle, horses, pigs, sheep, goats, dogs, cats, or rodents such as rats and mice.

[0032] The apparatus and method of the present invention provide treatment for a patient's medical condition, particularly for a type of cancer, by applying low-energy radiofrequency radiation specific to a particular disease to the patient. The apparatus uses a high-precision frequency synthesizer to generate radiofrequency EMFs that are amplitude-modulated at identified tumor-specific frequencies for application to the patient during treatment.

[0033] The system of this disclosure is used to affect cellular function or dysfunction in warm-blooded mammals. The system comprises one or more controllable low-energy electromagnetic energy generator circuits for generating one or more radio frequency output signals. One or more generator circuits are provided, which are also for receiving control information from a programmed control information source, or for communicating with one or more generator circuits. One or more generator circuits may include a programmable field-programmable gate array (FPGA) configured for the digital synthesis of fully modulated digital signals using one or more direct digital synthesizers (DDS). The FPGA generates the modulated digital signal by numerical calculations based on a carrier frequency digital signal and a modulated frequency digital signal. The fully modulated digital signals generated by the FPGA are, in view of a key improvement of the present invention, adapted to precisely control the amplitude modulation frequency, preferably within an accuracy of 1 / 10,000, more preferably within an accuracy of 1 / 100,000, and most preferably within an accuracy of 1 / 1,000,000 (ppm) with long-term stability of + / - 5.3 ppm, for one or more determined or predetermined reference amplitude modulation frequencies selected from the range of 0.1 Hz to 150,000 Hz, more preferably within an accuracy of 100,000 to 99,000 Hz. Furthermore, FPGA synthesis of the fully modulated digital signals allows for the simultaneous implementation of other types of modulation and various modulation frequency combinations. Moreover, such digital synthesis also makes it possible for the resolution to be independent of the actual modulation frequency. The fully modulated digital signals can be converted to analog RF output signals using a suitable digital-to-analog (DAC) converter. The system further includes connection or coupling points for connecting or coupling to a conductive applicator for applying one or more amplitude-modulated low-energy radiation at the precisely controlled modulation frequencies to warm-blooded mammalian subjects.

[0034] While this disclosure describes the use of modulated digital signals, analog formats and analog-modulated signals may also be used, as described in the “365 Patent.”

[0035] As used herein, the term “precisely controlled” means that modulated low-energy electromagnetic radiation at an intentionally determined or predetermined modulation frequency should preferably be modulated within a resolution of about 0.1 Hz, more preferably about 0.05 Hz, and most preferably about 3 to about 5 milliHz (0.003 to 0.005 Hz). For example, if one of the one or more determined or predetermined modulation frequencies applied to a warm-blooded mammalian subject is about 2000 Hz, then precise control should result in such modulated low-energy radiation being produced at frequencies between about 1999.995–1999.997 Hz and about 2000.003–2000.005 Hz.

[0036] The key is that the radiation is at a very low and safe energy level, which is the condition for low absorption levels. The reason is that physiological exchange or electrical impulse flow within warm-blooded animals (which are affected by the application of radiation in this invention) is also thought to be at a very low energy level. In any case, in that region (at or near the point of contact or proximity induction of the conductive applicator with the subject being treated), the specific absorption rate (SAR) should be between approximately 0.02 and approximately 400 mmW / kg.

[0037] Even more important for achieving the intended biological therapeutic effect is that the stability of the radiation is maintained during the radiation, and such stability is preferably at least about 10 -5 , more preferably at least about 10 -6 , and most preferably at least about 10 -7 This should be the case. Stability is determined by dividing the relative frequency deviation by the desired frequency, for example, 0.01Hz (deviation) / 1,000Hz (desired frequency) = 10 -5 That is the case.

[0038] Referring here to Figure 1, a system 100 for treating cancer in a subject may include a radiation device 101 that communicates with the subject 110. The radiation device 101 may be configured to provide modulated RF electromagnetic radiation (hereinafter, “output signal”) to the subject 110 via a probe 102 at a desired frequency. In certain embodiments, the output signal has, but is not limited to, various control parameters such as session duration, sequence of frequencies applied in session, and duration of each applied frequency. The applied frequencies and their corresponding durations may be determined based on the type of tumor being treated. Specifically, the selection of such an output signal is based on a predetermined output signal to provide a beneficial therapeutic effect to a group of subjects or patients pre-diagnosed with a specific poor health condition. The above output signal may be provided by a radiation device 101 adapted to generate an EMF output signal at a specific predetermined modulation frequency. Various types of modulation may be used, but are not limited to, amplitude modulation, frequency modulation, and phase modulation. The output signal is preferably generated at a tumor-specific amplitude modulation (AM) frequency.

[0039] In certain embodiments, the probe 102 may be a conductive applicator for applying one or more electromagnetic radiations to a warm-blooded mammalian subject, for example, via conductive, inductive, capacitive, radioactive coupling, or a combination thereof. One form of the applicator may include a conductive probe, for example, a mouthpiece inserted into the mouth of the subject being treated. The probe may be adapted for application to any mucous membrane of the subject (e.g., by being positioned within or on the surface of the oral cavity, nose, eye, urethra, anus, and / or vaginal cavity), or for physical contact with the skin of the patient (e.g., an insulated probe in contact with the subject's ear, head, neck, etc.), or for any other means.

[0040] In other embodiments, the EMF output signal is applied to the subject via an antenna that does not have direct physical contact with the subject. In such embodiments, the subject may be in a chamber exposed to the EMF output signal, or the subject may be kept near the broadcasting antenna for the EMF output signal for the duration of the treatment.

[0041] The probe 102 can be connected to the radiation device 101, for example, via a coaxial cable 104.

[0042] Referring now to Figure 2, a block diagram showing an exemplary radiation device 101 is shown. As shown in Figure 2, the radiation device 101 comprises a controller 201, memory 202, oscillator 203, digital frequency synthesizer 204, digital-to-analog (DAC) converter 205, amplifier 206, filter 207, directional coupler 208, impedance transformer 209, power supply 210, and communication interface 211. Optionally, the radiation device 101 may also include a display 212, a user interface 213, and other output configuration devices 214 (e.g., LEDs, speakers, etc.).

[0043] In certain embodiments, the controller 201 may act as a controller of the radiator 101 to control the operation of one or more of the radiator 101's components. The controller 201 may be communicably coupled to various components of the radiator 101 via, for example, an address bus, a data bus, and input / output lines (not shown herein). The timing of the controller 201 may be provided by a system clock (not shown herein) operating at any clock frequency suitable for the type of processor. Generally, the controller 201 is configured to control the operation of one or more of the radiator 101's components to generate a desired form of modulated low-energy electromagnetic radiation for application to a target via the probe 102.

[0044] The level of applied power is preferably controlled by the controller 201 so that the specific absorption rate (SAR) of energy absorbed by the patient ranges from approximately 1 microwatt to approximately 50 watts per kilogram of tissue. The power level is preferably controlled to yield an SAR of approximately 100 microwatts to approximately 10 watts per kilogram of tissue. Most preferably, the power level is controlled to yield an SAR of approximately 0.02 milliwatts to approximately 400 milliwatts per kilogram of tissue. These SARs are possible in any tissue of the patient.

[0045] The frequency of electromagnetic radiation may be specific to the tumor, as described in more detail below.

[0046] Referring here to Figure 4, a typical controller 400 is shown comprising a processor 402, random access memory (RAM) 403, non-volatile memory 404, device-specific circuitry 401, and an input / output (I / O) interface 405. Alternatively, the RAM 403 and / or non-volatile memory 404 may be included in the processor 402, as well as the device-specific circuitry 401 and the I / O interface 405. The processor 402 may be, for example, a commercially available microprocessor, a custom processor, a field-programmable gate array (FPGA), an application-specific integrated circuit (ASIC), discrete logic, etc. The RAM 403 is typically used to hold variable data, stack data, executable instructions, etc.

[0047] According to various approaches, the non-volatile memory 404 may comprise any type of non-volatile memory, but is not limited to, electrically erasable programmable read-only memory (EEPROM), flash programmable read-only memory (PROM), battery-backed RAM, or a hard disk drive. However, the non-volatile memory 404 is typically used to hold executable firmware and any non-volatile data, including program instructions that can be executed to cause the processor 402 to perform specific functions.

[0048] In some embodiments, the I / O interface 405 may include a communication interface that allows the processor 402 to communicate with devices outside the controller. Examples of communication interfaces include, but are not limited to, serial interfaces such as RS-232, USB (Universal Serial Bus), Small Computer System Interface (SCSI), Ethernet, RS-422, or wireless communication interfaces such as Wi-Fi, Bluetooth®, Near Field Communication (NFC), or other wireless interfaces. The controller 400 can communicate with external devices via the communication interface 405 using any communication protocol, such as an Automation / Drive Interface (ADI).

[0049] According to the various approaches described and / or proposed herein, the controller may have a single processor or controller, or it may have multiple processors or controllers, or multiple cores within a processor chip.

[0050] Memory 202 may be any storage device capable of storing information for later retrieval, and may be configured to store data for the operation of the radiator 101. For example, memory 202 may be a magnetic medium-based storage device (such as a card, tape, disk, or drum), a semiconductor memory-based storage device (such as an erasable programmable read-only memory (EPROM), an electrically erasable programmable read-only memory (EEPROM), or a non-volatile random-access memory (RAM)), a mechanical information storage device (such as a punch card or cam), and / or an optical storage device (such as a compact disc read-only memory (CD-ROM)).

[0051] Memory 202 may contain control information specifying various controllable parameters (used by controller 201) of the modulated low-energy radiation applied to the target via probe 102. Such controllable parameters may include, but are not limited to, the frequency and amplitude of the output signal, the duration of the radiation, the power level of the radiation, the duty cycle of the radiation (i.e., the ratio of on-time to off-time of the pulsed radiation applied during treatment), the order of application of various modulation frequencies for a particular application, the total number of treatments prescribed for a particular target and the duration of each treatment, and combinations thereof.

[0052] For example, Figure 5 shows an exemplary amplitude-modulated output signal that can be applied to a target in a series of applications of various modulation frequencies across a range from the lowest to the highest frequency, when each modulation frequency is applied for a predetermined period of time. As described above, this disclosure describes the use of digital signals (carrier frequency signals and / or modulation frequency signals), but the use of analog signals for generating the modulation frequencies of this disclosure is within the scope of this disclosure. Methods and systems for generating analog signals are described in the “365 Patents”.

[0053] In certain embodiments, a carrier frequency digital signal and a modulation frequency digital signal (described below) can be selected to drive the probe 102 with an amplitude-modulated output signal. The carrier frequency digital signal may be approximately 1 kHz to 5000 MHz, or approximately 0.1 to 1000 MHz, or approximately 1 to 500 MHz, or approximately 1 to 100 MHz, or approximately 5 to 50 MHz, or approximately 10 MHz to approximately 40 MHz, or approximately 15 MHz to approximately 30 MHz, or any other frequency that can utilize the target body as an antenna (e.g., 27 MHz). One or more modulation frequencies may be determined to be emitted simultaneously or arranged to form a modulated signal. The modulation frequency digital signal may be approximately 0.1 Hz to 150,000 Hz, more preferably 100 Hz to 99,000 Hz, and may be determined and selected based on the medical condition or type of cancer being treated (as described below).

[0054] In certain embodiments, memory 202 may also store event data corresponding to the radiation device 101, user information (e.g., authentication data, medical information, etc.), troubleshooting instructions, etc. Examples of event data include, but are not limited to, error logs, usage history and related data, treatment information, battery information, etc. Such event data may be used to monitor patient compliance and detect problems related to the function and handling of the device. Information or data stored in memory 202 may be retrieved using the communication interface 211 directly and / or indirectly (e.g., via a docking station for charging the radiation device 101). Such information may then be used by a physician or other clinician to evaluate the patient's treatment compliance and effectiveness. Treatment information may include, for example, the number of treatments applied over a given period, the actual date and time of each treatment, the number of treatments attempted, treatment compliance (i.e., whether the probe was in place during the treatment session), and the cumulative dose at a particular modulation frequency.

[0055] The digital frequency synthesizer 204 may be a programmable logic device (PLD), such as a field-programmable gate array (FPGA), and may be configured to provide digital synthesis of a fully modulated output signal. Those skilled in the art will understand that the implementation of digital synthesis can be similarly used when implemented in other PLDs. Figure 3 shows a block diagram of an exemplary digital frequency synthesizer 204.

[0056] As shown in Figure 3, the digital frequency synthesizer 204 may include a carrier frequency direct digital synthesizer (DDS) 301, a modulation frequency DDS 302, one or more control registers 303, a phase-locked loop (PLL) frequency multiplier 304, and an arithmetic logic unit (ALU) 305.

[0057] Direct Digital Synthesis (DDS) is a more common method for generating radio frequency (RF) signals due to its high performance and low cost. A DDS creates an RF signal using a reference clock supplied from an external source and data programmed into the DDS's registers. The DDS uses the reference clock to create an internal system clock as a multiple of the reference clock. The DDS uses the system clock to read the data programmed into the registers and create a digital signal output. The DDS also generates a synchronization clock used by external hardware to synchronize it with the DDS's internal system clock. The carrier frequency DDS301 and modulation frequency DDS302 may include a core architecture consisting of a phase accumulator that uses data programmed into control register 303 to set the output frequency and phase offset. A sinusoidal or cosine lookup table from phase to amplitude of the output eliminates high-frequency sampling images for outputting a pure sinusoidal digital signal. In certain embodiments, the carrier frequency DDS301 may be an M-bit DDS (e.g., a 32-bit sine wave DDS), and the modulation frequency DDS302 may be an N-bit DDS (e.g., a 32-bit sine wave DDS). Successfully used digital signal forms include square wave form, sine wave form, rectified sine wave, triangular wave, or other waveforms, and / or combinations thereof.

[0058] The control register 303 can receive data and / or instructions for setting the output frequency and phase offset of the output digital signal from the controller 201.

[0059] The carrier frequency DDS301 can generate an M-bit carrier frequency digital signal, and the modulation frequency DDS302 can generate an N-bit modulated frequency digital signal. The N-bit modulated frequency digital signal can be modified to control the modulation coefficient of the modulated frequency digital signal before being input to the ALU305. In one embodiment, the ALU305 can instantly numerically calculate a digital output signal modulated from the carrier frequency digital signal and the modulated frequency digital signal. For example, the digital frequency synthesizer 204 can output a K-bit (e.g., 12-bit) parallel modulated digital output signal. It should be noted that the ALU305 can be configured to numerically calculate a digital output signal for providing amplitude modulation, frequency modulation, and / or phase modulation.

[0060] The modulated digital output signal can optionally undergo further amplitude modulation in a digital multiplier (not shown here) before being converted to an analog RF output.

[0061] Furthermore, the digital frequency synthesizer 204 includes a PLL frequency multiplier configured to generate internal system clocks for the carrier frequency DDS301 and modulation frequency DDS302 using a reference clock generated by the clock oscillator 203. The clock oscillator 203 may be a high-precision temperature-compensated crystal oscillator with an initial accuracy of + / - 1 ppm. In an exemplary embodiment, the internal system clock may be set to 128 MHz and the reference clock may be set to 16 MHz.

[0062] While Figure 3 shows a single modulation frequency DDS302, it should be noted that this disclosure is not so limiting, and a digital frequency synthesizer may comprise one or more modulation frequency generators that enable the simultaneous transmission of multiple modulation frequency digital signals.

[0063] Referring back to Figure 2, the modulated digital output signal from the digital frequency synthesizer 204 is input to the DAC converter 205 to generate an analog RF signal. The RF signal from the DAC converter 205 is followed by an amplifier 206 (e.g., a linear RF power amplifier in bridge configuration), an arbitrary transformer (e.g., a balloon) (not shown here), a filter circuit 207 (e.g., a fifth-order elliptic Kauer filter), and an output to the probe 102. The filter circuit 207 may be connected to the probe 102 via a coaxial cable 104 and an impedance transformer 209 (configured to substantially match the impedance of the target impedance to the output impedance of the radiator 101). When the probe 102 is applied to the patient's mouth, the probe / patient combination is 150+j 200 Impedance measurements determined that the complex impedance was on the order of ohms. The impedance transformer 209 helps to match this complex impedance to the impedance of the coaxial cable, and consequently to the output impedance of the filter circuit 207. This facilitates power transmission and minimizes reflections. In a further example, the conductive isolated probe 102 is used at a frequency around 433 MHz, coupled to the outer ear channel. At such frequency bands, and with this coupling method, the probe design may differ, and the values ​​of the matched elements may even be different or omitted. In that case, probe 102 may be considered an antenna adapted to a capacitive coupler or capacitive load.

[0064] In certain embodiments, the output from the filter circuit 207 can pass through a directional coupler 208. The output signal from the directional coupler 208 can be supplied to two ADC inputs of the controller 201. Here, the amplitude and ratio of the two signals allow the controller 201 to continuously monitor both the output power / frequency of the signal in the probe 102 and the quality of the probe's contact with the target. This information can be used by the controller 201 to determine whether electromagnetic radiation is present at a desired frequency and power. The controller 201 then takes appropriate action, for example, displaying an error message on the display 212, providing appropriate correction signals to one or more components of the radiator 101, determining and controlling the amount of power applied to the target, evaluating the patient's treatment compliance, and recording a mark of the patient's treatment compliance in the memory 202 for later analysis and evaluation by the physician or other clinician.

[0065] The directional coupler 208 can be operated to couple a portion of the energy radiated by the filter circuit 207 to a detection circuit via an output connector. The output connector is connected to the primary input of the directional coupler, and the coaxial cable is connected to the primary output of the directional coupler. The directional coupler has two secondary outputs, each connected to a detection circuit. The first detection circuit functions to detect the amount of energy applied to the patient, and the second detection circuit functions to detect the amount of energy reflected from the patient. The first detection circuit is connected to the positive input of the differential amplifier via a resistor divider. The second detection circuit is connected to the negative input of the differential amplifier via a resistor divider. The output of the differential amplifier indicates the difference between the power transmitted to the patient by the filter circuit and the power reflected from the patient, and therefore indicates the amount of energy absorbed by the patient. The output of the differential amplifier is applied to an analog-to-digital converter (ADC) or comparator, the output of which is connected to the controller 201.

[0066] The complete digital synthesis of the modulated digital signals in the digital frequency synthesizer 204, combined with a linear output stage, enables the modulation of applied radiation using other modulation types in addition to amplitude modulation.

[0067] Furthermore, the radiator 101 may include a power supply 210 for supplying power to one or more of its components. The power supply 210 may be an energy storage system such as a battery, supercapacitor, lithium-ion battery, fuel cell, or other energy storage. The power supply 210 can be recharged using direct or inductive charging from a power source such as an AC power outlet or docking station. In certain embodiments, the controller 201 may monitor the power level of the power supply 210 and provide a warning to the user when the power level reaches a threshold level. In addition, the controller 201 may take actions based on the power level, such as switching off (and / or entering a low-power mode) the radiator 101 or one or more of its components.

[0068] Optionally, the docking station may be included in a system (not shown herein) configured to recharge the power supply 210. The docking station may include components such as a communication interface, a user authentication module, an activation module (for activating the radiator 101), or any other components that are currently or hereafter known.

[0069] Furthermore, the radiator 101 may include a communication interface 211 that enables the controller 201 to communicate with external devices such as servers, electronic devices, and docking stations. Examples of communication interfaces include, but are not limited to, serial interfaces such as RS-232, Universal Serial Bus (USB), Small Computer System Interface (SCSI), Ethernet, RS-422, or wireless communication interfaces such as Wi-Fi, Bluetooth®, Near Field Communication (NFC), or other wireless interfaces. The controller 201 can communicate with external devices via the communication interface 211 using any communication protocol, such as an Automation / Drive Interface (ADI).

[0070] As described above, the radiator 101 may also include a display 212 (which can display various indicators / warnings of the operation of the radiator 101), a user interface 213 (e.g., a keyboard, microphone, touch interface, etc. configured to suit user instructions), and other output configuration devices 214 (e.g., LEDs, speakers, etc.).

[0071] In certain embodiments, the radiation device 101 may include an activation module (not shown herein) for activating the radiation device 101 for a specific treatment session. The treatment session may be user-specific and determined based on authentication information received from the user. For example, a treatment session may be activated for the user depending on the user's medical condition. Various parameters of a treatment session may include, but are not limited to, the total duration of radiation in the treatment session, the power level of radiation, the duty cycle of radiation (i.e., the ratio of on-time to off-time of pulsed radiation applied during treatment), the order of application of various modulation frequencies for a particular application, and the total number of treatments prescribed for a particular subject and the duration of each treatment, as well as combinations thereof.

[0072] The activation module may receive authentication information from the user, for example, via a user interface (e.g., fingerprint, retinal scan, login credentials, etc.), an activation card that communicates with the activation interface of the radiator 101 (e.g., an RFID chip card, an ISO chip card, a contactless (NFC) card, etc.), and / or an external device that communicates with the radiator 101, such as a docking station.

[0073] The controller 201 of the radiation device 101 may operate to analyze information provided by the directional coupler to determine and control the amount of power delivered to the patient, assess the patient's treatment compliance, and optionally record an indication of the patient's treatment compliance in memory 202 for later analysis and evaluation by a physician or other clinician.

[0074] Examples of treatments performed on patients include tumor types of the brain, bladder, colorectal, kidney, mesothelial, neuroendocrine, liver, biliary tract, lung, breast, ovarian, pancreatic, prostate, and thyroid. Treatments have involved applying a carrier signal amplitude-modulated at a specially defined frequency in the range of approximately 0.1 to approximately 150,000 Hz with very high precision and stability. The carrier signal may be approximately 1 kHz to 5000 MHz, or approximately 0.1 to 1000 MHz, or approximately 1 to 500 MHz, or approximately 1 to 100 MHz, or approximately 5 to 50 MHz, or approximately 10 MHz to approximately 40 MHz, or approximately 15 MHz to approximately 30 MHz, or any other frequency that can utilize the target body as an antenna (e.g., 27 MHz). One or more modulation frequencies may be radiated simultaneously or arranged to form the modulation signal. The modulated frequency digital signal may be between approximately 0.1 Hz and approximately 150,000 Hz, more preferably between approximately 100 Hz and approximately 99,000 Hz. One or more modulation frequencies may be determined and selected based on the medical condition or type of cancer being treated. Further examples of treatment modes (at specific, precisely controlled AM frequencies) for specific types of tumors are described in detail below.

[0075] Figure 6 shows an example of internal hardware that may be included in any of the electronic components of the radiator 101. The electric bus 600 functions as an information highway interconnecting other illustrated components of the hardware. The processor 605 is the central processing unit of the system and is configured to perform the calculations and logical operations necessary to execute program instructions. As used in this document and the claims, the terms “processor” and “processing unit” may refer to a single processor or any number of processors in a set of processors that collectively perform a set of operations, such as a central processing unit (CPU), a graphics processing unit (GPU), a remote server, or a combination thereof. Read-only memory (ROM), random-access memory (RAM), flash memory, hard drives, and other devices capable of storing electronic data constitute an example of a memory device 625. A memory device may include a single device or a set of devices in which data and / or instructions are stored.

[0076] An optional display interface 630 may enable information from bus 600 to be displayed on display device 635 visually, graphically, or in alphanumeric format. An audio interface and audio output (such as a speaker) may also be provided. Communication with external devices may occur using various communication devices 640, such as wireless antennas, RFID tags, and / or short-range or near-field wireless communication transceivers, each of which may optionally be communicatively connected to other components of the device via one or more communication systems. The communication devices 640 may be configured to be communicatively connected to communication networks such as the Internet, a local area network, or a cellular data network.

[0077] The hardware may also include a user interface sensor 645 that enables the reception of data from input devices 650 such as a keyboard, mouse, joystick, touchscreen, touchpad, remote control, pointing device, and / or microphone. Digital image frames may also be received from a camera 620 capable of capturing video and / or still images. The hardware may also include one or more sensors 660 such as a position sensor (Global Positioning System), temperature sensor, pulse rate sensor, heart rate monitor, and resistance sensor.

[0078] Frequencies effective in treating specific medical conditions or cancers may be discovered using any currently known or hereafter known methods. Frequency discovery may involve exposing one or more subjects pre-diagnosed with a specific health condition (e.g., a specific type of cancer) to a precise modulation frequency applied to one or more subjects and measuring variations in the physiological responses of one or more of the patients. The frequencies determined in this manner may also be screened against healthy subjects to determine disease-specific modulation frequencies. Control measures may be obtained by exposing one or more subjects not suffering from a specific health condition (e.g., a specific type of cancer) to a modulation frequency applied to one or more subjects and measuring variations in the physiological responses of one or more of the patients. For example, frequency discovery may involve measuring variations in skin electrical resistance, pulse amplitude, and / or blood pressure of subjects while they are exposed to a modulation frequency generated using the methods and systems disclosed herein. For frequency discovery, subjects may be exposed to modulation frequencies ranging from approximately 0.1 Hz to approximately 150,000 Hz in increments (e.g., from approximately 50 Hz to approximately 150 Hz, preferably from approximately 75 Hz to approximately 125 Hz). Variations in skin electrical resistance, pulse amplitude, and / or blood pressure may also be measured. Whenever changes are observed in the measured skin electrical resistance (threshold change), pulse amplitude (approximately 1-2 beats), and / or blood pressure (threshold change), exposure to the corresponding modulation frequency may be increased in increasingly smaller increments (e.g., 10 Hz). -4 ~10 -3The process can be repeated using Hz. The frequency that elicits the best biofeedback response is selected as a tumor-specific frequency. For example, if variations in pulse amplitude are used, the best biofeedback response may be defined by the magnitude of the increased amplitude and / or the number of pulses accompanied by the increased amplitude. Such frequency detection can be performed in subjects at various disease stages, disease progression, stable disease, and / or partial responses. The selection of a specific frequency may be carried out according to the method described in Barbault et al. 2009 J. Exp. Clin. CancerRes. 28(1):51.

[0079] Using the methods described above, the methods and systems of this disclosure provide, but are not limited to, novel, safe therapies for multiple types of cancer, including, but are not limited to, breast cancer, pancreatic cancer, non-small cell and small cell lung cancer, neuroendocrine tumors, non-Hodgkin lymphoma, adenocarcinoma, head and neck cancer, gastric cancer, glioblastoma, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma, thyroid cancer, prostate cancer, rhabdomyosarcoma, multiple myeloma, leukemia, and colorectal cancer.

[0080] The following are amplitude modulation frequencies that have been found to be effective in treating various types of cancer. In general, it may be preferable that all frequencies determined to be specific to a particular type of cancer be applied to the treatment of subjects suffering from the indicated form of cancer. However, a limited number of determined frequencies, for example, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed frequencies, may also produce beneficial effects. [Table 1A-1] [Table 1A-2] [Table 1A-3] [Table 1A-4] [Table 1A-5] [Table 1A-6] [Table 1A-7] [Table 1A-8]

[0081] In certain embodiments, the cancer-specific AM frequencies provided in Table A may be used in combination with one or more AM frequencies disclosed in the “365 Patent.” One or more AM frequencies in Table A may be combined with one or more frequencies such as those provided in Tables 2, 4, 7, 13, 16, 18, 20 and 23-32 below. In preferred embodiments, frequencies of 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more are used in methods for the treatment of cancer. These frequencies are selected from Table A and optionally selected from Tables 2, 4, 7, 13, 16, 18, 20 and 23-32, provided that at least one or more frequencies are selected from Table A.

[0082] By applying an electromagnetic field amplitude-modulated at a frequency specific to a particular cancer to a patient, the apparatus and methods described herein for the treatment of various types of cancer may be used as independent cancer treatments or in combination with other currently known or future cancer treatments. The apparatus and methods described herein may be used in combination with surgical intervention, radiotherapy and / or chemotherapy.

[0083] When used in combination with other cancer treatments, the therapeutic methods described herein may be used as adjuvant or neoadjuvant therapies in the treatment of cancer. In the case of neoadjuvant therapy, the therapeutic methods described herein are administered to the subject before the primary treatment. Such neoadjuvant therapies may be applied to reduce the extent and / or size of the cancer before using a more curative therapeutic intervention, or to reduce the risk of recurrence and / or metastasis after primary treatment. Using the methods disclosed as neoadjuvant therapy may make primary treatment easier, more likely to succeed, thereby reducing side effects and / or improving the outcomes of a broader treatment. Primary treatments may be surgical interventions, radiotherapy, and / or chemotherapy.

[0084] The treatment methods described herein may be used as adjuvant therapies administered in addition to primary therapies to improve their effectiveness. Primary therapies may be surgery, radiotherapy, and / or chemotherapy. Adjuvant therapies may be administered concurrently with and / or after primary therapies. Adjuvant therapies may be used to reduce or prevent cancer recurrence after a subject has been treated with a primary therapy such as surgery, radiotherapy, and / or chemotherapy.

[0085] Breast cancer treatment

[0086] Breast cancer may be treated according to the methods disclosed herein by applying breast cancer-specific amplitude modulation frequencies. Breast cancer-specific frequencies are shown in Table 1 below. Patients with breast cancer may be treated with any number of frequencies shown in Table 1; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed breast cancer-specific frequencies may be used for the treatment of breast cancer. While the following table shows specific frequencies for the treatment of breast cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating breast cancer are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0087] [Table 1B]

[0088] In certain embodiments, the frequencies listed above may be used in combination with one or more of the frequencies disclosed in the “365 Patent.” Specifically, the therapies for the treatment of breast cancer according to this disclosure may include applications of one, some, or all of the above frequencies with one or more of the frequencies disclosed in Table 2 for breast cancer. Alternatively, and / or further, the frequencies disclosed in the “365 Patent” may be used in the treatment of breast cancer using the methods and systems described herein.

[0089] [Table 2]

[0090] One or more AM frequencies from Table 1 may be used in combination with one or more frequencies shown in Table 2. In a preferred embodiment, frequencies of 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more are used in methods for the treatment of breast cancer. The frequencies are selected from Table 1 and optionally from Table 2, provided that at least one or more frequencies are selected from Table 1.

[0091] Treatment of neuroendocrine tumors

[0092] Neuroendocrine tumors can be treated according to the methods disclosed herein by applying neuroendocrine tumor-specific amplitude modulation frequencies. Neuroendocrine tumor-specific frequencies are shown in Table 3 below. Patients with neuroendocrine tumors can be treated with any number of frequencies shown in Table 3, however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed neuroendocrine tumor-specific frequencies may be used for the treatment of neuroendocrine tumors. While the following table shows specific frequencies for the treatment of neuroendocrine tumors, it should be noted that this disclosure is not so limited, and other frequencies found to be effective for the treatment of neuroendocrine tumors are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0093] [Table 3]

[0094] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the “365 Patent.” Specifically, the therapies for the treatment of neuroendocrine tumors according to this disclosure may include the application of some or all of the above frequencies with one or more of the frequencies disclosed in Table 4 for neuroendocrine carcinomas. Alternatively and / or further, the frequencies disclosed in the “365 Patent” may be used in the treatment of neuroendocrine tumors using the methods and systems described herein.

[0095] [Table 4]

[0096] One or more AM frequencies from Table 3 may be combined with one or more frequencies as shown in Table 4. In a preferred embodiment, frequencies of 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more are used in methods for the treatment of breast cancer. The frequencies are selected from Table 3 and optionally from Table 4, provided that at least one or more frequencies are selected from Table 3.

[0097] Treatment of non-Hodgkin lymphoma

[0098] Non-Hodgkin lymphomas can be treated according to the methods disclosed herein by applying amplitude modulation frequencies specific to non-Hodgkin lymphomas. The tumor-specific frequencies for non-Hodgkin lymphomas are shown in Table 5 below. Patients with non-Hodgkin lymphomas may be treated with any number of frequencies shown in Table 5, however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more of the enumerated non-Hodgkin lymphoma-specific frequencies may be used in the treatment of non-Hodgkin lymphoma tumors. While the following table shows specific frequencies for the treatment of non-Hodgkin lymphoma tumors, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in the treatment of non-Hodgkin lymphoma tumors are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although this is not precise.

[0099] [Table 5]

[0100] Treatment of pancreatic adenocarcinoma

[0101] Pancreatic adenocarcinoma can be treated according to the methods disclosed herein by applying amplitude modulation frequencies specific to pancreatic adenocarcinoma. The frequencies specific to pancreatic adenocarcinoma are shown in Table 6 below. Patients with pancreatic adenocarcinoma may be treated with any number of frequencies shown in Table 6, however, it is preferable to use as many frequencies as possible that are generally practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the enumerated specific frequencies may be used for the treatment of pancreatic adenocarcinoma. While the following tables provide specific frequencies for the treatment of pancreatic adenocarcinoma, it should be noted that this disclosure is not so limited, and other frequencies found to be effective for the treatment of pancreatic adenocarcinoma are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0102] [Table 6]

[0103] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the “365 Patent.” Specifically, the therapeutic methods for the treatment of pancreatic adenocarcinoma according to this disclosure may include the application of some or all of the above frequencies with one or more of the frequencies disclosed in Table 7. Alternatively and / or further, the frequencies disclosed in the “365 Patent” may be used to treat the pancreatic adenocarcinoma condition using the methods and systems described herein.

[0104] [Table 7]

[0105] One or more AM frequencies from Table 6 may be used in combination with one or more frequencies shown in Table 7. In a preferred embodiment, frequencies of 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more are used in methods for the treatment of pancreatic adenocarcinoma. The frequencies are selected from Table 6 and optionally from Table 7, provided that at least one or more frequencies are selected from Table 6.

[0106] Treatment of head and neck cancer

[0107] Head and neck cancers can be treated according to the methods disclosed herein by applying head and neck cancer-specific amplitude modulation frequencies. Head and neck cancer-specific frequencies are shown in Table 8 below. Patients with head and neck cancer may be treated with any number of frequencies shown in Table 8; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, more than 10, 15 or more of the listed head and neck cancer-specific frequencies may be used for the treatment of head and neck cancer. While the following table shows specific frequencies for the treatment of head and neck cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating head and neck cancer are within the scope of this disclosure. Furthermore, each frequency listed below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although this is not precise.

[0108] [Table 8]

[0109] Stomach cancer treatment

[0110] Gastric cancer may be treated according to the methods disclosed herein by applying gastric cancer-specific amplitude modulation frequencies. Gastric cancer-specific frequencies are shown in Table 9 below. Patients with gastric cancer may be treated with any number of frequencies shown in Table 9; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed gastric cancer-specific frequencies may be used for the treatment of gastric cancer. While the following table shows specific frequencies for the treatment of gastric cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating gastric cancer are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0111] [Table 9]

[0112] Treatment for glioblastoma

[0113] Glioblastoma can be treated according to the methods disclosed herein by applying glioblastoma-specific amplitude modulation frequencies. Glioblastoma-specific frequencies are shown in Table 10 below. Patients with glioblastoma may be treated with any number of frequencies shown in Table 10; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the enumerated glioblastoma-specific frequencies may be used for the treatment of glioblastoma. While the following table shows specific frequencies for the treatment of glioblastoma, it should be noted that this disclosure is not so limited, and other frequencies found to be effective for the treatment of glioblastoma are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0114] [Table 10]

[0115] Treatment of squamous cell carcinoma of the anal canal

[0116] Squamous cell carcinoma of the anal canal can be treated according to the methods disclosed herein by applying amplitude modulation frequencies specific to squamous cell carcinoma of the anal canal. The frequencies specific to squamous cell carcinoma of the anal canal are shown in Table 11 below. Patients with squamous cell carcinoma of the anal canal can be treated with any number of frequencies shown in Table 11; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, or 80 or more of the enumerated frequencies specific to squamous cell carcinoma of the anal canal can be used for the treatment of squamous cell carcinoma of the anal canal. While the following table shows specific frequencies for the treatment of squamous cell carcinoma of the anal canal, it should be noted that this disclosure is not so limited, and other frequencies found to be effective for the treatment of squamous cell carcinoma of the anal canal are within the scope of this disclosure. Furthermore, each frequency listed below contains a value that is not exact but is close to a numerical value or range (i.e., within + / - 0.1 Hz).

[0117] [Table 11]

[0118] Treatment of hepatocellular carcinoma

[0119] Hepatocellular carcinoma can be treated according to the methods disclosed herein by applying hepatocellular carcinoma-specific amplitude modulation frequencies. Hepatocellular carcinoma-specific frequencies are shown in Table 12 below. Patients with hepatocellular carcinoma may be treated with any number of frequencies shown in Table 12; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed hepatocellular carcinoma-specific frequencies may be used for the treatment of hepatocellular carcinoma. While the following table shows specific frequencies for the treatment of hepatocellular carcinoma, it should be noted that this disclosure is not so limited, and other frequencies found to be effective for the treatment of hepatocellular carcinoma are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0120] [Table 12]

[0121] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the “365 Patent.” Specifically, the therapeutic methods for the treatment of hepatocellular carcinoma according to this disclosure may include the application of some or all of the above frequencies with one or more of the frequencies disclosed in Table 13 for hepatocellular carcinoma. Alternatively, and / or further, the frequencies disclosed in the “365 Patent” may be used in the treatment of hepatocellular carcinoma conditions using the methods and systems described herein.

[0122] [Table 13]

[0123] One or more AM frequencies from Table 12 may be used in combination with one or more frequencies shown in Table 13. In a preferred embodiment, frequencies of 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more are used in methods for the treatment of hepatocellular carcinoma. The frequencies are selected from Table 12 and optionally from Table 13, provided that at least one or more frequencies are selected from Table 12.

[0124] Treatment of bile duct cancer

[0125] Cholangiocarcinoma can be treated according to the methods disclosed herein by applying cholangiocarcinoma-specific amplitude modulation frequencies. Cholangiocarcinoma-specific frequencies are shown in Table 14 below. Patients with cholangiocarcinoma can be treated with any number of frequencies shown in Table 14, however, it is preferable to use as many frequencies as possible that are generally practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed cholangiocarcinoma-specific frequencies may be used for the treatment of cholangiocarcinoma. The following table shows specific frequencies for the treatment of cholangiocarcinoma, but it should be noted that this disclosure is not so limited, and other frequencies found to be effective for the treatment of cholangiocarcinoma are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0126] [Table 14]

[0127] Treatment of mesothelioma

[0128] Mesothelioma can be treated according to the methods disclosed herein by applying mesothelioma-specific amplitude modulation frequencies. Mesothelioma-specific frequencies are shown in Table 15 below. Patients with mesothelioma may be treated with any number of frequencies shown in Table 15; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the enumerated mesothelioma-specific frequencies may be used for the treatment of mesothelioma. While the following table shows specific frequencies for the treatment of mesothelioma, it should be noted that this disclosure is not so limited, and other frequencies found to be effective for the treatment of mesothelioma are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0129] [Table 15]

[0130] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the “365 Patent.” Specifically, the therapeutic methods for treating mesothelioma according to this disclosure may include the application of some or all of the above frequencies with one or more of the frequencies disclosed in Table 16 for mesothelioma. Alternatively, and / or further, the frequencies disclosed in the “365 Patent” may be used in the treatment of mesothelioma using the methods and systems described herein.

[0131] [Table 16]

[0132] One or more AM frequencies from Table 15 may be used in combination with one or more frequencies shown in Table 16. In preferred embodiments, frequencies of 10 or more, 15 or more, or 20 or more, 25 or more; or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more are used in methods for the treatment of mesothelioma. The frequencies are selected from Table 15 and optionally from Table 16, provided that at least one or more frequencies are selected from Table 15.

[0133] Treatment of thyroid cancer

[0134] Thyroid cancer can be treated according to the methods disclosed herein by applying thyroid cancer-specific amplitude modulation frequencies. Thyroid cancer-specific frequencies are shown in Table 17 below. Patients with thyroid cancer may be treated with any number of frequencies shown in Table 17; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the enumerated thyroid cancer-specific frequencies may be used for the treatment of thyroid cancer. While the following table shows specific frequencies for the treatment of thyroid cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating thyroid cancer are within the scope of this disclosure. Furthermore, each frequency listed below includes a value that is not exact but close to a numerical value or range (i.e., within + / - 0.1 Hz).

[0135] [Table 17]

[0136] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the “365 Patent.” Specifically, the therapies for the treatment of thyroid cancer according to this disclosure may include the application of some or all of the above frequencies with one or more of the frequencies disclosed in Table 18 for thyroid cancer. Alternatively and / or further, the frequencies disclosed in the “365 Patent” may be used in the treatment of thyroid cancer using the methods and systems described herein.

[0137] [Table 18]

[0138] One or more AM frequencies from Table 17 may be used in combination with one or more frequencies shown in Table 18. In preferred embodiments, frequencies of 10 or more, 15 or more, or 20 or more, 25 or more; or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more are used in methods for the treatment of thyroid cancer. The frequencies are selected from Table 17 and optionally from Table 18, provided that at least one or more frequencies are selected from Table 17.

[0139] Treatment of prostate cancer

[0140] Prostate cancer may be treated according to the methods disclosed herein by applying amplitude modulation frequencies specific to prostate cancer. Prostate cancer-specific frequencies are shown in Table 19 below. Patients with prostate cancer may be treated with any number of frequencies shown in Table 19; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the enumerated prostate cancer-specific frequencies may be used for the treatment of prostate cancer. While the following table shows specific frequencies for the treatment of prostate cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating prostate cancer are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0141] [Table 19]

[0142] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the “365 Patent.” Specifically, the therapies for the treatment of prostate cancer according to this disclosure may include the application of some or all of the above frequencies with one or more of the frequencies disclosed in Table 20 for prostate cancer. Alternatively and / or further, the frequencies disclosed in the “365 Patent” may be used in the treatment of prostate cancer using the methods and systems described herein.

[0143] [Table 20]

[0144] One or more AM frequencies from Table 19 may be used in combination with one or more frequencies shown in Table 20. In a preferred embodiment, frequencies of 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more are used in a method for the treatment of prostate cancer. The frequencies are selected from Table 19 and optionally from Table 20, provided that at least one or more frequencies are selected from Table 19.

[0145] Treatment of rhabdomyosarcoma

[0146] Rhabdomyosarcoma can be treated according to the methods disclosed herein by applying rhabdomyosarcoma-specific amplitude modulation frequencies. Rhabdomyosarcoma-specific frequencies are shown in Table 21 below. Patients with rhabdomyosarcoma may be treated with any number of frequencies shown in Table 21, however, it is preferable to use as many frequencies as possible that are generally practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the enumerated rhabdomyosarcoma-specific frequencies may be used in the treatment of rhabdomyosarcoma. While the following table shows specific frequencies for the treatment of rhabdomyosarcoma, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in the treatment of rhabdomyosarcoma are within the scope of this disclosure. Furthermore, each frequency described below includes a numerical or range-like value (i.e., within + / - 0.1 Hz), although these values ​​are not exact.

[0147] [Table 21]

[0148] Treatment of colorectal cancer

[0149] Colorectal cancer can be treated according to the methods disclosed herein by applying colorectal cancer-specific amplitude modulation frequencies. Colorectal cancer-specific frequencies are shown in Table 22 below. Patients with colorectal cancer may be treated with any number of frequencies shown in Table 22; however, it is preferable to use as many frequencies as possible that are generally practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed colorectal cancer-specific frequencies may be used in the treatment of colorectal cancer. While the following table shows specific frequencies for the treatment of colorectal cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in the treatment of colorectal cancer are within the scope of this disclosure. Furthermore, each frequency listed below includes a value that is not exact but is close to a numerical value or range (i.e., within + / - 0.1 Hz).

[0150] [Table 22]

[0151] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the “365 Patent” (reproduced below). Specifically, the therapeutic methods for the treatment of colorectal cancer according to this disclosure may include the application of some or all of the frequencies listed above with one or more of the frequencies disclosed in Table 23 for colorectal cancer. Alternatively, and / or further, the frequencies disclosed in the “365 Patent” may be used in the treatment of colorectal cancer using the methods and systems described herein.

[0152] [Table 23]

[0153] One or more AM frequencies from Table 22 may be used in combination with one or more frequencies shown in Table 23. In preferred embodiments, frequencies of 10 or more, 15 or more, or 20 or more, 25 or more; or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more are used in methods for the treatment of colorectal cancer. The frequencies are selected from Table 22 and optionally from Table 23, provided that at least one or more frequencies are selected from Table 22.

[0154] In certain embodiments, the frequencies disclosed in the “365 Patent” may be used to treat medical conditions using the methods and systems described herein.

[0155] Treatment for ovarian cancer

[0156] Ovarian cancer can be treated according to the methods disclosed herein by applying ovarian cancer-specific amplitude modulation frequencies. Ovarian cancer-specific frequencies are shown in Table 24 below. Patients with ovarian cancer can be treated with any number of frequencies shown in Table 24, however, it is preferable to use as many frequencies as possible that are generally practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the enumerated ovarian cancer-specific frequencies may be used for the treatment of ovarian cancer. While the following table shows specific frequencies for the treatment of ovarian cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating ovarian cancer are within the scope of this disclosure.

[0157] [Table 24-1] [Table 24-2]

[0158] Treatment for kidney cancer

[0159] Renal cancer can be treated according to the methods disclosed herein by applying renal cancer-specific amplitude modulation frequencies. Renal cancer-specific frequencies are shown in Table 25 below. Patients with renal cancer may be treated with any number of frequencies shown in Table 25; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more of the enumerated renal cancer-specific frequencies may be used in the treatment of renal cancer. While the following table shows specific frequencies for the treatment of renal cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating renal cancer are within the scope of this disclosure.

[0160] [Table 25]

[0161] Bladder cancer treatment

[0162] Bladder cancer can be treated according to the methods disclosed herein by applying bladder cancer-specific amplitude modulation frequencies. Bladder cancer-specific frequencies are shown in Table 26 below. Patients with bladder cancer may be treated with any number of frequencies shown in Table 26, however, it is preferable to use as many frequencies as possible that are generally practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more of the enumerated bladder cancer-specific frequencies may be used in the treatment of bladder cancer. While the following table shows specific frequencies for the treatment of bladder cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in the treatment of bladder cancer are within the scope of this disclosure.

[0163] [Table 26]

[0164] Lung cancer treatment

[0165] Lung cancer may be treated according to the methods disclosed herein by applying lung cancer-specific amplitude modulation frequencies. Lung cancer-specific frequencies are shown in Table 27 below. Patients with lung cancer may be treated with any number of frequencies shown in Table 27; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, or 80 or more of the listed lung cancer-specific frequencies may be used in the treatment of lung cancer. While the following table shows specific frequencies for the treatment of lung cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating lung cancer are within the scope of this disclosure.

[0166] [Table 27]

[0167] Treatment of leiomyosarcoma

[0168] Leiomyosarcoma can be treated according to the methods disclosed herein by applying leiomyosarcoma-specific amplitude modulation frequencies. Leiomyosarcoma-specific frequencies are shown in Table 28 below. Patients with leiomyosarcoma may be treated with any number of frequencies shown in Table 28, however, it is preferable to use as many frequencies as possible that are generally practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more of the enumerated leiomyosarcoma-specific frequencies may be used for the treatment of leiomyosarcoma. The following table shows specific frequencies for the treatment of leiomyosarcoma, but it should be noted that this disclosure is not so limited, and other frequencies found to be effective for the treatment of leiomyosarcoma are within the scope of this disclosure.

[0169] [Table 28]

[0170] Treatment of leukemia and chronic lymphocytic cancer

[0171] Leukemia and chronic lymphocytic cancer can be treated according to the methods disclosed herein by applying amplitude modulation frequencies specific to leukemia and chronic lymphocytic cancer. The frequencies specific to leukemia and chronic lymphocytic cancer are shown in Table 29 below. Patients with leukemia and chronic lymphocytic cancer may be treated with any number of frequencies shown in Table 29; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, more than 10, 15 or more of the enumerated frequencies specific to leukemia and chronic lymphocytic cancer may be used in the treatment of leukemia and chronic lymphocytic cancer. While the following table shows specific frequencies for the treatment of leukemia and chronic lymphocytic cancer, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in the treatment of leukemia and chronic lymphocytic cancer are within the scope of this disclosure.

[0172] [Table 29]

[0173] Treatment of myeloma

[0174] Myeloma can be treated according to the methods disclosed herein by applying myeloma-specific amplitude modulation frequencies. Myeloma-specific frequencies are shown in Table 30 below. Patients with myeloma may be treated with any number of frequencies shown in Table 30; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, 10 or more, 15 or more, or 20 or more of the enumerated myeloma-specific frequencies may be used in the treatment of myeloma. While the following table shows specific frequencies for the treatment of myeloma, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating myeloma are within the scope of this disclosure.

[0175] [Table 30]

[0176] Lymphoma treatment

[0177] Lymphoma can be treated according to the methods disclosed herein by applying lymphoma-specific amplitude modulation frequencies. Lymphoma-specific frequencies are shown in Table 31 below. Patients with lymphoma may be treated with any number of frequencies shown in Table 31; however, it is generally preferable to use as many frequencies as possible that are practical for treating the patient. Therefore, more than 10, 15 or more of the enumerated lymphoma-specific frequencies may be used for the treatment of lymphoma. While the following table shows specific frequencies for the treatment of lymphoma, it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating lymphoma are within the scope of this disclosure.

[0178] [Table 31]

[0179] Treatment of brain tumors

[0180] Brain tumors can be treated according to the methods disclosed herein by applying brain tumor-specific amplitude modulation frequencies. Brain tumor-specific frequencies are shown in Table 32 below. Patients with brain tumors can be treated with any number of frequencies shown in Table 32, however, it is preferable to use as many frequencies as possible that are generally practical for treating the patient. Thus, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more of the listed brain tumor-specific frequencies can be used to treat brain tumors. The following table shows specific frequencies for the treatment of brain tumors, but it should be noted that this disclosure is not so limited, and other frequencies found to be effective in treating brain tumors are within the scope of this disclosure.

[0181] [Table 32]

[0182] The following is an overview of exemplary uses of the electronic device of the present invention and cancer-specific frequencies for patient treatment.

[0183] Example A A 79-year-old man was diagnosed with hepatocellular carcinoma (HCC) and was negative for hepatitis A and B. He underwent a left hepatectomy the following month, which revealed the presence of poorly differentiated HCC. The tumor had a maximum diameter of 10 cm and was staged as pT3NxMx. Five months after diagnosis, the patient had evidence of disease progression with four new lesions identified in the right lobe of the liver and new mediastinal lymphadenopathy, and chemoembolization with doxorubicin and Lipiodol was performed the following month. A follow-up MRI performed the following month showed disease progression. Treatment with sorafenib was initiated when the patient's performance status was ECOG1 with KPS 80% and ChildePew A6. Special concurrent therapy with a TheraBionic device emitting 206 hepatocellular carcinoma (HCC) specific frequencies was administered for 3 hours daily. The patient demonstrated a complete response to the marker, as alpha-fetoprotein (AFP) levels decreased from 92,620.0 international units / ml (IU / ml) before the start of treatment to 4.18 IU / ml. This was measured one year after the initial diagnosis and four months after the initiation of treatment at an HCC-specific frequency.

[0184] Nexavar was discontinued at the beginning of the third year after the initial diagnosis due to unbearable side effects. One month after discontinuation of Nexavar, there was evidence of early disease progression, with a doubling of AFP levels and nearly doubling of liver enzyme levels ASAP, ALAT, and gamma GT. The patient's tumor-specific frequencies were re-examined using the method described above. Analysis revealed pulse pressure changes in additional HCC-specific frequencies. 50 HCC frequencies were added to the 206 HCC frequencies, meaning the patient began receiving 256 frequencies with each treatment. A new abdominal MRI obtained seven months later revealed the appearance of a new tumor nodule. The following month, the patient was re-examined using the method described above. Analysis revealed pulse pressure changes in 12 additional HCC-specific frequencies, bringing the total to 268 HCC-specific frequencies. The same approach was used whenever there was clear progression due to changes in AFP levels and / or significant enlargement of existing tumor masses and / or the appearance of new tumor masses. The addition of new HCC-specific frequencies resulted in a significant reduction or stabilization of tumor mass, as well as a decrease in AFP levels. In the final year of treatment, the patient received a total of 422 HCC-specific frequencies.

[0185] The patient received treatment with the TheraBionic device for 67 months when he was unable to receive regular treatment due to a hip fracture following a fall, general weakness, and worsening renal failure. He died 6 months later. In summary, the addition of HCC-specific frequencies resulted in repeated objective clinical responses, assessed both radiologically and by tumor markers, and extended survival (more than 6 years) in a patient with rapidly progressing hepatocellular carcinoma.

[0186] Example B

[0187] An 87-year-old male with a long history of type 2 diabetes was diagnosed with advanced, unresectable multiple hepatocellular carcinomas. He refused treatment with Nexavar and requested special-use treatment with a TheraBionic device. He began treatment with 313 HCC-specific frequencies two months after diagnosis. The patient's disease remained stable for 13 months, when there was evidence of disease progression according to RECIST criteria. He began treatment with 355 HCC-specific frequencies within the following month. A follow-up abdominal MRI obtained two months later revealed the presence of necrosis in two lesions and stable disease in the other lesions. Therefore, an additional 42 HCC-specific frequencies were added, resulting in a radioactive reaction. A follow-up abdominal MRI obtained two months later showed stable disease according to RECIST criteria. A follow-up liver MRI obtained three months later showed disease progression according to RECIST criteria, with the appearance of new liver lesions. Two weeks later, the patient was examined in the manner described above, and changes in pulse pressure were observed with an additional 49 HCC frequencies. Therefore, the patient began treatment with 404 frequencies at that time. Repeated abdominal MRIs obtained three months later showed a stable disease. The patient did well for the next two months, when there was gastrointestinal bleeding due to esophageal varices. The patient refused treatment for the esophageal varices and died later that month. Thus, the treatment of this patient demonstrates the clinical effectiveness of additional HCC frequencies leading to both an objective response and a stable disease.

[0188] background

[0189] A portable, programmable device, as described herein, capable of delivering low-level amplitude-modulated electromagnetic fields has been developed. This device emits a 27 MHz radio frequency signal, precisely amplitude-modulated at cancer-specific frequencies ranging from 0.1 to 150 kHz. The device is connected to a spoon-like coupler, which is placed in the mouth of the patient during treatment.

[0190] Example 1: Treatment of breast cancer Breast cancer may be treated according to the methods disclosed herein by applying breast cancer-specific amplitude modulation frequencies. Breast cancer-specific frequencies are shown in Table 33 below.

[0191] [Table 33]

[0192] Example 2: Treatment of neuroendocrine tumors Neuroendocrine tumors may be treated according to the methods disclosed herein by applying neuroendocrine tumor-specific amplitude modulation frequencies. Neuroendocrine tumor-specific frequencies are shown in Table 34 below.

[0193] [Table 34]

[0194] Example 3: Treatment of non-Hodgkin lymphoma Non-Hodgkin lymphoma tumors may be treated according to the methods disclosed herein by applying amplitude modulation frequencies specific to non-Hodgkin lymphoma. The frequencies specific to non-Hodgkin lymphoma tumors are shown in Table 35 below.

[0195] [Table 35]

[0196] Example 4: Treatment of pancreatic adenocarcinoma Pancreatic adenocarcinoma can be treated according to the methods disclosed herein by applying amplitude modulation frequencies specific to pancreatic adenocarcinoma. The frequencies specific to pancreatic adenocarcinoma are shown in Table 36 below.

[0197] [Table 36]

[0198] Example 5: Treatment of head and neck cancer Head and neck cancers may be treated according to the methods disclosed herein by applying head and neck cancer-specific amplitude modulation frequencies. Head and neck cancer-specific frequencies are shown in Table 37 below.

[0199] [Table 37]

[0200] Example 6: Treatment of gastric cancer Gastric cancer may be treated according to the methods disclosed herein by applying gastric cancer-specific amplitude modulation frequencies. Gastric cancer-specific frequencies are shown in Table 38 below.

[0201] [Table 38]

[0202] Example 7: Treatment of glioblastoma Glioblastoma can be treated according to the methods disclosed herein by applying glioblastoma-specific amplitude modulation frequencies. Glioblastoma-specific frequencies are shown in Table 39 below.

[0203] [Table 39]

[0204] Example 8: Treatment of squamous cell carcinoma of the anal canal Squamous cell carcinoma of the anal canal can be treated according to the methods disclosed herein by applying amplitude modulation frequencies specific to squamous cell carcinoma of the anal canal. The frequencies specific to squamous cell carcinoma of the anal canal are shown in Table 40 below.

[0205] [Table 40]

[0206] Example 9: Treatment of hepatocellular carcinoma Hepatocellular carcinoma can be treated according to the method disclosed herein by applying the amplitude-modulated frequency specific to hepatocellular carcinoma. The frequencies specific to hepatocellular carcinoma are shown in Table 41 below.

[0207]

Table 41

[0208] Example 10: Treatment of cholangiocarcinoma Cholangiocarcinoma can be treated according to the method disclosed herein by applying the amplitude-modulated frequency specific to cholangiocarcinoma. The frequencies specific to cholangiocarcinoma are shown in Table 42 below.

[0209]

Table 42

[0210] Example 11: Treatment of mesothelioma Mesothelioma can be treated according to the method disclosed herein by applying the amplitude-modulated frequency specific to mesothelioma. The frequencies specific to mesothelioma are shown in Table 43 below.

[0211]

Table 43

[0212] Example 12: Treatment of thyroid cancer Thyroid cancer can be treated according to the method disclosed herein by applying the amplitude-modulated frequency specific to thyroid cancer. The frequencies specific to thyroid cancer are shown in Table 44 below.

[0213]

Table 44

[0214] Example 13: Treatment of prostate cancer Prostate cancer may be treated according to the methods disclosed herein by applying amplitude modulation frequencies specific to prostate cancer. The prostate cancer-specific frequencies are shown in Table 45 below.

[0215] [Table 45]

[0216] Example 14: Treatment of rhabdomyosarcoma Rhabdomyosarcoma can be treated according to the methods disclosed herein by applying rhabdomyosarcoma-specific amplitude modulation frequencies. Rhabdomyosarcoma-specific frequencies are shown in Table 46 below.

[0217] [Table 46]

[0218] Example 15: Treatment of colorectal cancer Colorectal cancer can be treated according to the methods disclosed herein by applying colorectal cancer-specific amplitude modulation frequencies. Colorectal cancer-specific frequencies are shown in Table 47 below.

[0219] [Table 47]

[0220] Conclusion:

[0221] The treatment of cancer by the methods and apparatus described herein is a novel, safe, and promising treatment for multiple types of cancer. Following extended trials, it was determined that the application of the frequencies provided herein to the target population enhances the efficacy of the treatment and results in therapeutic effects in patients whose tumors have become resistant to treatment. Therefore, it is preferable that most (i.e., 50% or more) or all of the determined and enumerated frequencies be applied to the target population. The mechanism for including additional frequencies is due to either or both the synergistic effects interacting between the applied frequencies or between cells affected by the therapeutic and additive effects of the additional frequencies.

[0222] Even more noteworthy is the fact that various patients suffering from the same type of tumor cell proliferation actually exhibit the above-mentioned physiological responses at the same clearly defined AM frequencies. Furthermore, AM frequencies that differ slightly from the enumerated frequencies (less than 0.001% at higher frequencies) generally result in reduced or no physiological response being induced by subjects exposed to excitation at such very slightly different frequencies. Taking these decisions into account, the electronic system of the present invention can be adapted to screen subjects for physiological responses across a wide range of frequencies to determine the presence or absence of tumor cells, and preferably to focus on which defined frequencies evoke a physiological response. Since these frequencies generally coincide with the defined frequencies enumerated in one of the above examples or other examples that may be developed, the nature of the tumor can be determined. Thus, the electronic system of the present invention is a valuable diagnostic tool for diagnosing the presence or absence and identity of tumor cell growth or type of cancer. Furthermore, the electronic system of the present invention is valuable for predicting whether a patient will benefit from the application of a given set of modulation frequencies. Thus, the system has the capability to predict the response to treatment, thereby increasing the likelihood of selecting the optimal treatment mode.

[0223] A clearly defined frequency procedure is preferably applied consecutively for a determined time, for example, 3 seconds for each frequency, although several frequencies may be applied simultaneously, or in any order or random order. This means that a cycle of application involving 180 frequencies would take nearly 10 minutes. However, beneficial effects can also arise from applying clearly defined individual frequencies for varying durations, such as 3 seconds, 6 seconds, etc.

[0224] The therapeutic dose applied to subjects suffering from tumor cell proliferation or the presence of cancer is determined by the duration of application of low-energy electromagnetic radiation to the subject and depends on the nature of the cancer and the subject's overall condition. However, the greatest experience has generally been gained in treating terminally ill subjects who are expected to survive for approximately three months or less and who have agreed to discontinue alternative forms of cancer treatment such as chemotherapy or radiotherapy. In these severe cases, a user-friendly treatment duration, such as three 1-hour treatments per day, is recommended. However, continuous application may be possible and desirable by using alternative application methods, i.e., methods other than mouse probes.

[0225] Although the present invention has been described in particular embodiments, other alternatives, modifications, and variations will be apparent to those skilled in the art. Therefore, it is intended that all such alternatives, modifications, and variations be included within the spirit and scope of the appended claims.

Claims

1. A method of treating a person suffering from cancer, This includes exposing the subject to low-energy high-frequency radiation, wherein the low-energy high-frequency radiation includes one or more amplitude-modulated output signals. The one or more amplitude-modulated output signals have a carrier frequency of approximately 1 kHz to 5000 MHz and an amplitude modulation frequency of approximately 0.1 Hz to approximately 150,000 Hz, wherein the amplitude modulation frequency is selected to be a frequency specific to cancer, and The subject is a method of treatment using one or more cancer-specific amplitude modulation frequencies selected from Table A, or 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more. Table 1-1 Table 1-2 Table 1-3 Table 1-4 Table 1-5 Table 1-6

2. The method according to claim 1, wherein the amplitude modulation frequencies specific to cancer, which are 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more, are selected from Table A, and are arbitrarily selected from any of Tables 2, 4, 7, 13, 16, 18, 20 and 23-32, wherein at least one or more frequencies are selected from Table A.

3. The method according to claim 1 or 2, wherein the cancer is selected from the group consisting of breast cancer, neuroendocrine tumors, non-Hodgkin lymphoma, adenocarcinoma, head and neck cancer, gastric cancer, glioblastoma, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma, thyroid cancer, prostate cancer, rhabdomyosarcoma, lung cancer, kidney cancer, ovarian cancer, bladder cancer, leiomyosarcoma, myeloma, lymphoma, leukemia, chronic lymphocytic carcinoma, brain tumor, and colorectal cancer.

4. The method according to any one of claims 1 to 3, wherein the carrier frequency is approximately 0.1 to 1000 MHz, or approximately 1 to 500 MHz, or approximately 1 to 100 MHz, or approximately 5 to 50 MHz, or approximately 10 MHz to approximately 40 MHz, or approximately 15 MHz to approximately 30 MHz.

5. The method according to any one of claims 1 to 4, wherein the modulation frequency is from 100 Hz to 99,000 Hz.

6. The method according to any one of claims 1 to 5, wherein the frequency of each of the one or more modulated output signals is controlled with respect to a reference amplitude modulation frequency with an accuracy of 1 / 10,000, 1 / 100,000, or 1 / 1,000,000 (PPM).

7. Each of the one or more modulated output signals is at least 10 -５ Maintained in stability during radiation, or at least 10 -６ Maintained in stability during radiation, or at least 10 -７ The method according to any one of claims 1 to 6, which is maintained in stability during radiation.

8. The method according to any one of claims 1 to 7, wherein the specific absorption rate (SAR) of the low-energy radiofrequency radiation absorbed by the patient is approximately 1 microwatt per kilogram of tissue to approximately 50 watts per kilogram of tissue, approximately 100 microwatts per kilogram of tissue to approximately 10 watts per kilogram of tissue, or approximately 0.02 milliwatts per kilogram of tissue to approximately 400 milliwatts per kilogram of tissue.

9. The method according to any one of claims 1 to 8, wherein the low-energy radiofrequency radiation is applied to the target being treated via a conductive probe.

10. The method according to claim 9, wherein the conductive probe is configured to come into contact with the mucous membrane or skin of the target.

11. The method according to any one of claims 1 to 10, wherein the one or more modulated output signals are generated sequentially or simultaneously.

12. The method according to any one of claims 1 to 11, wherein the amplitude modulation frequency is determined or predetermined by a biofeedback process which includes measuring one or more physiological responses by the subject that has been previously diagnosed to have the type of cancer when the subject is exposed to the amplitude modulation frequency.

13. The method according to any one of claims 1 to 12, wherein the low-energy high-frequency radiation includes 40 or more modulated output signals, 50 or more modulated output signals, 60 or more modulated output signals, 70 or more modulated output signals, 70 or more modulated output signals, 90 or more modulated output signals, or 100 or more modulated output signals.

14. The method according to any one of claims 1 to 12, wherein the cancer is breast cancer, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 2

15. The method according to any one of claims 1 to 12, wherein the cancer is a neuroendocrine carcinoma, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or less. Table 3

16. The method according to any one of claims 1 to 12, wherein the cancer is non-Hodgkin lymphoma, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 4

17. The method according to any one of claims 1 to 12, wherein the cancer is an adenocarcinoma of the pancreas, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 5

18. The method according to any one of claims 1 to 12, wherein the cancer is a head and neck cancer, and the subject is treated with all of the frequencies, including 10 or more, 15 or more, or less. Table 6

19. The method according to any one of claims 1 to 12, wherein the cancer is gastric cancer, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or less. Table 7

20. The method according to any one of claims 1 to 12, wherein the cancer is glioblastoma, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 8

21. The method according to any one of claims 1 to 12, wherein the cancer is squamous cell carcinoma of the anal canal, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 9

22. The method according to any one of claims 1 to 12, wherein the cancer is hepatocellular carcinoma, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 10

23. The method according to any one of claims 1 to 12, wherein the cancer is cholangiocarcinoma, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 11

24. The method according to any one of claims 1 to 12, wherein the cancer is mesothelioma, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 12

25. The method according to any one of claims 1 to 12, wherein the cancer is thyroid cancer, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 13

26. The method according to any one of claims 1 to 12, wherein the cancer is prostate cancer, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 14

27. The method according to any one of claims 1 to 12, wherein the cancer is rhabdomyosarcoma, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or less. Table 15

28. The method according to any one of claims 1 to 12, wherein the cancer is colorectal cancer, and the subject is treated with all of the frequencies including 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more. Table 16

29. A device for treating a subject suffering from cancer, wherein the device is: A conductive applicator configured to apply low-energy high-frequency radiation to the aforementioned target, wherein the low-energy high-frequency radiation includes one or more amplitude-modulated output signals; and A frequency synthesizer configured to generate one or more amplitude-modulated output signals by coupling to a conductive applicator and generating a carrier frequency signal having a carrier frequency from approximately 1 kHz to 5000 MHz and an amplitude-modulated frequency signal having an amplitude-modulated frequency from approximately 0.1 Hz to approximately 150,000 Hz, wherein the amplitude-modulated frequency is selected to be a frequency specific to cancer. Equipped with, The apparatus wherein the amplitude modulation frequency signal includes 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the cancer-specific amplitude modulation frequencies selected from Table A. Table 17-1 Table 17-2 Table 17-3 Table 17-4 Table 17-5 Table 17-6

30. The apparatus according to claim 29, wherein the cancer is selected from the group consisting of breast cancer, neuroendocrine tumors, non-Hodgkin lymphoma, adenocarcinoma, head and neck cancer, gastric cancer, glioblastoma, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma, thyroid cancer, prostate cancer, rhabdomyosarcoma, lung cancer, kidney cancer, ovarian cancer, bladder cancer, leiomyosarcoma, myeloma, lymphoma, leukemia, chronic lymphocytic carcinoma, brain tumor, and colorectal cancer.

31. The apparatus according to claim 29 or 30, wherein the carrier frequency is approximately 0.1 to 1000 MHz, or approximately 1 to 500 MHz, or approximately 1 to 100 MHz, or approximately 5 to 50 MHz, or approximately 10 MHz to approximately 40 MHz, or approximately 15 MHz to approximately 30 MHz.

32. The aforementioned frequency synthesizer is A digital carrier frequency synthesizer configured to output the carrier frequency signal, A digital modulation frequency synthesizer configured to output one or more amplitude modulation frequency signals, An arithmetic logic unit (ALU) configured to numerically calculate one or more digital modulation signals in real time from the carrier frequency signal and the modulation frequency digital signal, A digital-to-analog converter (DAC) configured to convert the one or more digitally modulated signals into the one or more amplitude-modulated output signals, The apparatus according to any one of claims 29 to 31, which is a digital frequency synthesizer comprising

33. A device for treating a subject suffering from cancer, wherein the device is: A conductive applicator configured to apply low-energy high-frequency radiation to the aforementioned target, wherein the low-energy high-frequency radiation includes one or more amplitude-modulated output signals; A frequency synthesizer coupled to a conductive applicator, configured to generate one or more amplitude-modulated output signals by generating a carrier frequency signal having a carrier frequency from approximately 1 kHz to 5000 MHz and an amplitude-modulated frequency signal having an amplitude-modulated frequency from approximately 0.1 Hz to approximately 150,000 Hz, wherein the amplitude-modulated frequency is selected to be a frequency specific to cancer. Equipped with, The aforementioned frequency synthesizer is A digital carrier frequency synthesizer configured to output the carrier frequency signal, A digital modulation frequency synthesizer configured to output one or more amplitude modulation frequency signals, An arithmetic logic unit (ALU) configured to numerically calculate one or more digital modulation signals in real time from the carrier frequency signal and the modulation frequency digital signal, A digital-to-analog converter (DAC) configured to convert the one or more digitally modulated signals into the one or more amplitude-modulated output signals, A device that is a digital frequency synthesizer equipped with [a specific feature].

34. The apparatus according to claim 33, wherein the cancer is selected from the group consisting of breast cancer, neuroendocrine tumors, non-Hodgkin lymphoma, adenocarcinoma, head and neck cancer, gastric cancer, glioblastoma, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma, thyroid cancer, prostate cancer, rhabdomyosarcoma, lung cancer, kidney cancer, ovarian cancer, bladder cancer, leiomyosarcoma, myeloma, lymphoma, leukemia, chronic lymphocytic carcinoma, brain tumor, and colorectal cancer.

35. The apparatus according to claim 33 or 34, wherein the carrier frequency is approximately 0.1 to 1000 MHz, or approximately 1 to 500 MHz, or approximately 1 to 100 MHz, or approximately 5 to 50 MHz, or approximately 10 MHz to approximately 40 MHz, or approximately 15 MHz to approximately 30 MHz.

36. The apparatus according to any one of claims 33 to 35, wherein the modulation frequency is from 100 Hz to 99,000 Hz.

37. The apparatus according to any one of claims 33 to 36, wherein the digital frequency synthesizer further comprises a controller configured to control the frequency and power associated with the one or more amplitude-modulated output signals.

38. The apparatus according to any one of claims 33 to 37, further comprising a directional coupler for providing power and absorption information related to each of the one or more amplitude-modulated output signals in the controller.

39. The apparatus according to any one of claims 33 to 38, wherein the digital frequency synthesizer further comprises a phase-locked loop (PLL) frequency multiplier configured to set a system clock for one or more of the digital carrier frequency synthesizers or the digital modulation frequency synthesizers described below.

40. The apparatus according to any one of claims 33 to 39, wherein the digital carrier frequency synthesizer is a direct digital synthesizer (DDS).

41. The apparatus according to any one of claims 33 to 39, wherein the digital modulation frequency synthesizer is a direct digital synthesizer (DDS).

42. The apparatus according to any one of claims 28 to 41, wherein the frequency synthesizer is configured to sequentially or simultaneously generate the one or more amplitude-modulated output signals.

43. The apparatus according to any one of claims 28 to 42, wherein the conductive applicator is configured for insertion into the oral cavity of the subject receiving treatment.

44. The apparatus according to any one of claims 28 to 43, wherein the amplitude modulation frequency is determined or predetermined by a biofeedback process which includes observing or measuring a physiological response by the subject while the cellular function of the subject is excited by exposure of the subject to the emission of a modulated output signal.

Images